Switch to: References

Add citations

You must login to add citations.
  1. Dark Side of the Shroom: Erasing Indigenous and Counterculture Wisdoms with Psychedelic Capitalism, and the Open Source Alternative.Neşe Devenot, Trey Conner & Richard Doyle - 2022 - Anthropology of Consciousness 33 (2):476-505.
    Psychedelic or ecodelic medicines (e.g., psilocybin, ayahuasca, iboga) for the care and treatment of addiction, post‐traumatic stress disorder, cancer, cluster headaches, anxiety, and depression have surged to the forefront of discussions about mental health in the US, leading to the emergence of well‐capitalized biotech companies offering multimillion‐dollar IPOs. Venture capital website Pitchbook reports “continuing investor interest and growing acceptance of what until recently was seen as a fringe area of medicine.” As scholars, activists, and practitioners who have been healed by (...)
    Download  
     
    Export citation  
     
    Bookmark   4 citations  
  • Ethics of Psychedelic Use in Psychiatry and Beyond—Drawing upon Legal, Social and Clinical Challenges.Nuno Azevedo, Miguel Oliveira Da Silva & Luís Madeira - 2023 - Philosophies 8 (5):76.
    Background: Psychedelics are known for their powerful mental effects due to the activation of 5HT-2A receptors in the brain. During the 1950s and 1960s, research was conducted on these molecules until their criminalization. However, their clinical investigation as therapeutic tools for psychiatric disorders has revived the deontological ethics surrounding this subject. Questions arise as research on their therapeutic outcome becomes a reality. We aim to explore deontological ethics to understand the implications of psychedelics for the clinician, patient, and society. Results: (...)
    Download  
     
    Export citation  
     
    Bookmark  
  • History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers.Michaela Barber, John Gardner & Adrian Carter - forthcoming - Journal of Bioethical Inquiry:1-17.
    Background Psychedelic medicine is a rapidly growing area of research and policy change. Australia recently became the first country to legalize the prescription of psychedelics and serves as a case study of issues that may emerge in other jurisdictions. Despite their influence as a stakeholder group, there has been little empirical exploration of psychedelic researchers’ views on the development of psychedelic research and the ethical concerns. Methods We thematically analysed fourteen interviews with Australian psychedelic researchers. Results Three themes were constructed (...)
    Download  
     
    Export citation  
     
    Bookmark